Astria Therapeutics Inc News

Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersJun 4 16:10 ET

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive

BusinesswireMay 30 08:00 ET

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a

BusinesswireMay 24 08:00 ET

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the

BusinesswireMay 23 08:00 ET

Astria Therapeutics Is Maintained at Outperform by Oppenheimer

Astria Therapeutics Is Maintained at Outperform by Oppenheimer

Dow JonesMay 21 08:12 ET

Express News | Astria Therapeutics : Oppenheimer Cuts Target Price to $25 From $29

ReutersMay 21 08:10 ET

Express News | Oppenheimer Maintains Outperform on Astria Therapeutics, Lowers Price Target to $25

BenzingaMay 21 08:02 ET

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow JonesMay 10 15:11 ET

Express News | Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target

BenzingaMay 10 09:36 ET

Astria TherapeuticS GAAP EPS of -$0.38 Misses by $0.02

Seeking AlphaMay 10 01:54 ET

Express News | Astria Therapeutics Q1 2024 GAAP EPS $(0.38), Inline

BenzingaMay 9 17:36 ET

Astria Therapeutics 1Q Loss/Shr 38c >ATXS

Astria Therapeutics 1Q Loss/Shr 38c >ATXS

Dow JonesMay 9 16:24 ET

Astria Therapeutics Appointed Sunil Agarwal to Its Bd >ATXS

Astria Therapeutics Appointed Sunil Agarwal to Its Bd >ATXS

Dow JonesMay 9 16:24 ET

Express News | Astria Therapeutics Inc: Progressing to a Pivotal Phase 3 Trial, Expected to Initiate in Q1 2025 for Our Q3M Regimen

ReutersMay 9 16:11 ET

Express News | Astria Therapeutics Inc: Expects Cash, Cash Equivalents & Short-Term Investments as of March 31 to Be Sufficient to Fund Operations Into Mid-2027

ReutersMay 9 16:11 ET

Express News | Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

ReutersMay 9 16:10 ET

Express News | Astria Therapeutics Q1 Income From Operations USD -24.15 Million

ReutersMay 9 16:10 ET

Astria Therapeutics Inc | 10-Q: Quarterly report

SEC announcementMay 9 16:04 ET · Announcements

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

Business WireMay 8 08:00 ET

Express News | Astria Therapeutics Inc : H.c. Wainwright Cuts Target Price to $16 From $18

Moomoo 24/7Apr 23 06:14 ET